Perturbation to Cholesterol at the Neuromuscular Junction Confers Botulinum Neurotoxin A Sensitivity to Neonatal Mice

Baskaran Thyagarajan,*† Joseph G. Potian,† Joseph J. McArdle,† and Padmamalini Baskaran*

*School of Pharmacy, College of Health Sciences University of Wyoming, Laramie, Wyoming 82071 and †Department of Pharmacology and Physiology, Rutgers University, Newark, New Jersey 07103

To whom correspondence should be addressed at School of Pharmacy, University of Wyoming, 1000 East University Avenue, Laramie, WY 82071. Fax: (307) 766 2953. E-mail: bthyagar@uwyo.edu.

ABSTRACT

Botulinum neurotoxin A (BoNT/A) cleaves SNAP25 at the motor nerve terminals and inhibits stimulus evoked acetylcholine release. This causes skeletal muscle paralysis. However, younger neonatal mice (<P7; <7-days old) are resistant to the neuroparalytic effects of BoNT/A. That is, in vivo injection of BoNT/A at the innervations of Extensor digitorum longus muscle in the hindlimbs inhibited the toe spread reflex within 24 hours following BoNT/A injection in adult mouse and in older (>P7) mice. However, neonatal mice younger than 7 days-age remained unaffected by BoNT/A injection. Also, BoNT/A inhibited stimulus evoked acetylcholine release and stimulus-evoked twitch tension of diaphragm nerve muscle preparations (NMPs) of adult mouse and >P7 neonates but not that of <P7. Moreover, NMPs of <P7 showed decreased uptake of fluorescent BoNT/A compared to >P7. Further, cholesterol depletion using methyl-β-cyclodextrin (MβCD) sensitized <P7 neonates to BoNT/A and facilitated BoNT/A uptake into NMPs obtained from <P7 neonates. Further, MβCD (10 mM; 30 min pretreatment) increased the interaction between synaptic vesicle protein 2 and BoNT/A. Also, cholesterol depletion increased the miniature endplate current in adult NMPs. Interestingly, cholesterol replenishment, in vitro, delayed the onset of inhibitory effect of BoNT/A. Collectively, our data suggest that cholesterol rich lipid microdomains are involved in BoNT/A uptake mechanisms during development. Our data demonstrate that cholesterol depletion sensitized neonatal mice (<P7) to BoNT/A while replenishing cholesterol delayed the onset of inhibitory action of BoNT/A. This suggests that membrane cholesterol modulates neurotoxin sensitivity at the neuromuscular junction (NMJ).

Key words: neonatal neuromuscular junction; botulinum neurotoxin; cholesterol-rich lipid microdomains; synaptic vesicle protein; methyl-β-cyclodextrin.
At the motor nerve terminal (MNT) SNARE complex proteins regulate the docking and fusion of synaptic vesicle. The 7 serotypes of BoNTs (A through G) are produced by Clostridium botulinum. Botulinum neurotoxin A (BoNT/A) is the principal serotype and is a potential bioterror agent (Marks, 2004). BoNT/A holotoxin consists of a 100 kDa heavy chain (Hc, receptor binding domain) and a 50 kDa light chain (Lc) linked by a single disulfide bond. BoNT/A Hc binding to its receptors on the neural membrane sets the stage for endocytosis into the MNT. Separation of Lc and Hc takes place after translocation of Lc in the reducing cytosol (Pirazzini et al., 2015). The Hc translocates the Lc into the cytosol where it cleaves SNAP-25 and attenuates ACh release resulting in flaccid neuroparalysis of the innervated muscles in adult mice.

However, in early 1980s younger rats were reported to recover from botulinum-induced paralysis much more quickly than adults. In a study with neonatal mice, it was observed that intragastric administration of Clostridium botulinum spores to mice <7 days old showed resistance to botulinum intoxication (Sugiyama and Mills, 1978). In this research study, we report that neonatal mice, younger than 7 days of age (<P7) showed resistance to BoNT/A and that cholesterol depletion by MJCD sensitized these neonates to the neurotoxin. We analyzed this systematically by investigating the effects of BoNT/A in wild type and MjCD treated diaphragm nerve muscle preparations (NMPs) obtained from <P7, >P7 (older than 7 days of age) and adult mice.

Our data provide evidence for the role of cholesterol in the regulation of BoNT/A uptake mechanism. This knowledge is very useful for ensuring careful clinical use of BoNT/A when administered along with medications that perturb cellular cholesterol levels.

**MATERIALS AND METHODS**

**Surgical Procedure and Injections**

Adult and neonatal (age P3-P10) C57BL/6 wild type mice were used for the study. All protocols were conducted as per protocols approved by Institutional Animal Care and Use Committee. Aseptic techniques were used for surgical procedures in mice for in vivo experiments. Mice were anesthetized with intraperitoneal injection of a mixture of ketamine (80 mg/kg) and xylazine (10 mg/kg). A small incision in the skin at the knee region was made in the leg where the peroneal nerve enters into the muscle contractions in response to phrenic nerve stimulation. The central tendon of the hemidiaphragm muscle was tied to a Grass Force transducer connected to a Digidata 1440A (Molecular Devices, Sunnyvale, California). The data acquisition and analysis of mechanical responses of the isolated diaphragm to nerve stimulation were performed with PCLAMP 10 software (Molecular Devices Inc., USA). The muscle preparations were adjusted to optimal length for force generation and equilibrated for 15 min before stimulation at 1 Hz for data acquisition.

**Electrophysiology**

Measurement of miniature end plate potentials or currents and stimulus-evoked endplate potentials or currents recorded from diaphragm NMPs. Diaphragm NMPs with phrenic nerve were removed from adult mice or neonatal mice anesthetized with isoflurane followed by cervical dislocation. Isolated NMP were pinned to a Sylgard-lined Plexiglas chamber, and bathed in HRS (22 C) containing (mM) NaCl 135; KCl 5; CaCl2; MgCl2; 1 mM Na2HPO4, 5.5 and HEPES 5. In control preparations 0.75 μM α-conotoxin GIIIB (Alamone Labs, Israel) was added to the bath to inhibit muscle contractions in response to phrenic nerve stimulation. In experiments performed to study the effects of BoNT/A (10 pM) after in vitro exposure (bath application), the procedure was as described before (Thyagarajan et al., 2009). The EPPs in control muscles were recorded by blocking the contractions with α-conotoxin as described earlier. EPPs/EPCs and miniature end plate potentials (mEPPs) (~75 mV holding potential) were recorded from the endplate region by using single or 2 electrode voltage clamp technique as described previously in Thyagarajan et al. (2009). The signals were amplified by Axoclamp-2B amplifier (Axon Instruments, Foster City, California, USA), acquired and digitized (Digidata 1200, Axon Instruments) and analyzed with PCLAMP software (version 9.2, Axon Instruments). All experiments were performed at 22 C.

**Uptake of BoNT/A in neonate and adult mouse diaphragm NMPs.** Evaluation of neurotoxin uptake was studied in diaphragm preparations removed from neonates (P4 and P8) and adult mice. For analyzing BoNT/A uptake the diaphragms were pinned to a Sylgard-lined Plexiglas chamber and were bathed in 667 pM Alexa Fluor 647-labeled BoNT/A (Alexa Fluor dyes;
Invitrogen, Carlsbad, California) in HRS solution. The uptake of neurotoxin (667 PM Alexa Fluor 647) was initiated in response to nerve stimulation (1 Hz). NMPs were fixed in 4% formaldehyde phosphate-buffered saline (PBS) (room temperature [RT]) for 1 h followed by overnight incubation (4 °C) in 100 mM glycine in PBS. NMPs were then permeabilized with 1% Triton X-100 in PBS at 4 °C for 6 h followed by 3 washes with PBS and blocking with 2% bovine serum albumin in PBS overnight. Postsynaptic ACh receptors were labeled by exposing the fixed tissue to 1 ng/ml of Alexa Fluor 488-labeled α-bungarotoxin (α-BnTX) at 4 °C for 6 h. The muscle end-plate region was cut out and mounted with Vectashield on a slide and kept frozen at −20 °C before imaging in Carl Zeiss LSM-710 confocal microscope. The images were captured by exposing slides to appropriate argon laser beams (488 nm for αBnTX) and (647 nm for BoNT/A). Images were saved and represented as TIFF files.

**Cell Culture**

Mouse cholinergic neuroblastoma (Neuro 2a) cells were cultured in Dulbecco’s modified Eagle’s medium-F12 medium, pH 7.4, supplemented with 10% fetal bovine serum and antibiotics. Cells were exposed to 10 mM MjICD preincubation followed by 90 min. of treatment with 1 nM BoNT/A in 40 mM KCl containing HEPES Ringer Solution.

**Western Blotting/Immunoprecipitation**

Diaphragm NMPs were dissected from isoflurane-anaesthetized C57BL/6 mice. NMPs were either treated with buffer or with 10 PM BoNT/A (uptake stimulated either by 1 Hz neural stimulation or by exposing the tissues to 40 mM KCl containing HRS for 90 min. NMPs were then flash frozen in liquid nitrogen and stored at −80 °C until tissue was homogenized in PBS containing 1% Nonidet 40 and complete protease inhibitor cocktail (GE Healthcare, Little Chalfont, Buckinghamshire, UK). Homogenates of Neuro 2a cells were prepared in the same manner. After centrifuging the homogenate at 14,000 rpm for 10 min in the cold, the crude lysate (40 μg) was resolved via SDS-polyacrylamide gel electrophoresis after boiling in 1× aemml buffer. Immunoblotting was performed with anti-rabbit SV2 polyclonal antibody (detects all 3 SV2–SV2A, SV2B and SV2C; Developmental Study Hybridoma Bank, Iowa City, USA). For immunoprecipitation, the homogenized samples were precleared with Protein A Sepharose 4 beads and incubated with non-immune serum or specific antibody (SV2; AB2315387, DSHB, Iowa City, USA) overnight at 4 °C. Protein A beads were then added to samples for 2 h at 4 °C, pelleted by centrifugation and washed 3 times with lysis buffer (50 mM HEPES, pH 8.0/1 mM EDTA/150 mM NaCl, 1% Triton and protease inhibitors). Proteins were eluted with 1% SDS buffer, resolved by 7.5% SDS/PAGE, and analyzed by immunoblotting with BoNT/A Hc antibody.

**Cholesterol Depletion by MjICD and Cholesterol Supplementation**

Solutions of 10 mM MjICD or αCD (control) was prepared by dissolving it in sterile filtered HRS. For cholesterol supplementation, we used MjICD saturated with cholesterol (Ch-MjICD). Concentration of 3 μl of 10 mM MjICD, Ch-MjICD, or αCD was injected into right EDL of neonates. For in vitro experiments, 10 mM MjICD was used to deplete cholesterol 30 min. prior to 10 PM BoNT/A addition. Typically, for electrophysiological recordings to measure mEPP and EPP were made for the MjICD or αCD treated diaphragm NMPs.

**Data Analyses**

Data for all figures were expressed as mean ± SD for n = 8 mice, 16 NMPs and 30 endplates. The statistical significance between the population means was determined using Student’s t test and p values ≤ .05 were considered significant * and ** represent statistical significance for p < .05 and .01, respectively.

**RESULTS**

**BoNT/A Inhibits Stimulus-Evoked EPP and Twitch Tension in Adult Mouse and P7 Neonates but Not in P3 Neonates**

Experiments were performed in diaphragms isolated from adult mice and P7 and P3 neonates. Sample records of EPPs (1 Hz nerve-elicited) and the mean values for their amplitude are shown in Figure 1. Control recordings were obtained in the presence of μ-conotoxin to block muscle twitches (Figs. 1A–C). Control value for the EPPs was around 12 mv for adult, P7 and P3 MNT. Interestingly for adult and P7 diaphragms exposure to BoNT/A (10 PM) for 90 min produced block of neuromuscular transmission (NMT) as seen by lack of EPP response to even increased stimulus strength. On the contrary, NMP of P3 mouse was unaffected by the neurotoxin as shown by a robust EPP of about 11 mV which was followed by a small mEPP (Figure 1C).

The mean EPP amplitudes in NMP of muscles from adult, P7 and P3 diaphragm NMPs for before BoNT/A application were 12.22 ± 3.76, 11.94 ± 3.54, and 12.06 ± 3.12 mV, respectively, and 90 min after BoNT/A exposure were 0.10 ± 0.002, 0.08 ± 0.001, and 11.48 ± 3.06 mV, respectively. These results confirmed the finding that the MNT in neonate mice <P7 is resistant to BoNT/A-induced block of NMT.

Next, we analyzed the effect of BoNT/A on stimulus-evoked twitch tension in diaphragm NMPs isolated from adult, >P7 and <P7 mice. As illustrated in Figure 2, the stimulus evoked twitch tension values for adult and >P7 neonates were 100% and 1.02 ± 0.001% and 100% and 1.14 ± 0.002%, respectively, while that for <P7 neonates were 100% and 91.521% at 0 min and at 90 min. following BoNT/A treatment.

**Diaphragm NMPs of Neonates Do Not Endocytose BoNT/A**

In order to evaluate whether NMPs of neonates younger than 7 days endocytose BoNT/A, we performed stimulus evoked fluorescence BoNT/A uptake experiments in diaphragm of adult, P8 and P4 mice.

Experiments performed with BoNT/A labeled with Alexa Fluor 647 demonstrated that MNTs from diaphragms of mice (P < 7) failed to demonstrate toxin uptake into cholinergic nerves. The right-hand column of Supplementary Figure 1 represents confocal images of motor end-plates in adult, P8 and P4 NMPs labeled with Alexa Fluor 647–BoNT/A and the left-hand column shows the corresponding postsynaptic labeling by Alexa Fluor 488–α-BnTX.

**Chemicals and Drugs**

Sources were: BoNT/A was obtained from Metabiologics Inc., Madison, WI, USA. Alexa 467 labeled BoNT/A was purchased from (BBTech, Dartmouth, Massachusetts). BoNT/A light chain (LC/A) was a kind gift from Dr Bal Ram Singh, INADS, MA. Sources for other reagents were as follows: α-BnTX (Thermoscientific, USA), MjICD, α-cyclodextrin (αCD), water-soluble cholesterol and all other chemicals and drugs were obtained from Sigma-Aldrich (St Louis, MO, USA). SV2 antibody, which recognizes all 3 isoforms of SV2 (AB2315387) was obtained from Developmental Study Hybridoma Bank, Iowa City, USA. SNAP-25 antibody (NBP1-88769) was obtained from Novus Biologics USA.
Depletion of Cholesterol by MβCD Sensitizes Neonate Mouse MNT to BoNT/A

Membrane cholesterol is an important regulator of synaptic vesicle recycling (Puchkov and Haucke, 2013). Membrane cholesterol depletion by MβCD increases spontaneous vesicle fusion rates at the neuromuscular junction while decreased evoked release (Petrov et al., 2014; Rodrigues et al., 2013; Tarakanova et al., 2011). SV2 is a receptor for BoNT/A (Dong et al., 2006; Mahrhold et al., 2006; Weisemann et al., 2016) that is present in vesicles that fuse and release ACh at the MNT. Therefore, we evaluated whether depletion of cholesterol sensitizes neonatal mice to BoNT/A. To achieve this, we pretreated isolated MNPs with MβCD, and then evaluated the effect of BoNT/A on synaptic transmission in neonatal mice.
from < P7 neonates with MβCD (10 mM for 30 min. at RT) and then measured stimulus evoked endplate potentials (EPPs). As described in Figures 3A and B, BoNT/A alone did not inhibit EPPs in P3 MNPs while pretreatment with MβCD (10 mM for 30 min) conferred sensitivity to BoNT/A in P3 NMPs. The mean EPP amplitude ± STDEV for control (αCD; 10 mM 30 min), MβCD, BoNT/A (10 pM) and BoNT/A + MβCD (30 min pretreatment with 10 mM MβCD followed by 90 min. of BoNT/A treatment) were measured to be 8.76 ± 0.77, 8.94 ± 0.89, 8.44 ± 0.26, and 1.89 ± 0.012 mV, respectively. Further, the mEPP frequency for adult and P3 MNPs before and after MβCD treatment were determined to be 1.82 ± 0.31 and 2.88 ± 0.56 mV (adult) and 0.54 ± 0.14 and 0.88 ± 0.20 mV (P3), respectively.

Neuroparalysis After a Local Injection of BoNT/A in P3 Mice After MβCD
A single local injection of BoNT/A into EDL muscle of right hind limb of adult mouse produced paralysis which was evident as early as 24 h. post injection. The paralysis of right foot was seen by the lack of reflex spreading of toes when the mouse was lifted by its tail. The left foot from HRS injected EDL showed normal TSR (Figure 4). Similar injections of the neurotoxin in P3–P7 mice failed to demonstrate any paralysis of the hind limbs. Normally at this age the mice do not have righting reflex and the ability to move using their fore or hind limbs. This precluded measurement of TSR.

None of the neonates (P2–P6) that received BoNT/A showed any paralysis up to 2 months of observation period. The resistance to block of NMT was best demonstrated by injecting MβCD (3 μl of 10 mM) 30 min prior to BoNT/A injection. The percentages of neuroparalysis following the injection of BoNT/A in the adult and P8 mice and that following the injection BoNT/A postαCD, MβCD, or cholesterol saturated MβCD in P3 mice are shown in Figure 4.

Next, we analyzed the ability of BoNT/A to cause inhibition of stimulus-evoked twitch tension in P3 mice diaphragm NMPs following cholesterol depletion with MβCD (Figure 5). The twitch tension percentage at 0, 30, 60 and 90 min. post BoNT/A treatment in αCD or MβCD pretreated (10 mM; 30 min) NMPs are given in Table 1.

MβCD-Induced Cholesterol Depletion Enhances Uptake of BoNT/A by Nerve Terminal Membrane
Since cholesterol depletion sensitized the P3 neonates to BoNT/ A, we evaluated whether MβCD treatment stimulated BoNT/A uptake into P3 MNPs. As shown in Supplementary Figure 2, pre-treatment of the NMP with αCD failed to enhance the uptake of florescent labeled BoNT/A while MβCD pretreatment facilitated BoNT/A uptake into P3 (Supplementary Figure 2) and P4 NMPs (Supplementary Figure 5B) at 22°C.
We also measured the effect of MjCD treatment on stimulus-evoked twitch tension at 22°C (RT) and 37°C (Supplementary Figures 3A and B). We calculated the percent of twitch tension in adult diaphragm NMPS at time 0 and at time 120 min following pretreatment with 10 mM MjCD (Supplementary Figure 3C). MjCD pretreatment per se did not significantly decrease stimulus-evoked twitch tension of NMPS.

Since cholesterol depletion by MjCD < P7 sensitized neonates to BoNT/A, we evaluated whether MjCD treatment sped up the onset of inhibition of stimulus evoked endplate current (EPCs) in adult NMPS. We performed these experiments in EDS NMPS, which were exposed to either buffer (control; sCD) or MjCD (10 mM for 30 min) before exposure to BoNT/A. The EPC amplitudes (nA) at the beginning of the experiment and at 40 min and 90 min after BoNT/A exposure are shown in Figure 6. Table 2 shows the EPC amplitudes for these conditions.

Next, we evaluated the effect of MjCD pretreatment on BoNT/A-induced inhibition of twitch tension in P7 diaphragm NMPS. For this, we pretreated NMPS isolated from P7 (7-day-old mice) with 10 mM MjCD for 30 min and then measured the stimulus evoked twitch tension in the presence of either 10, 3, or 1 pM BoNT/A. We also measured the twitch tension in the presence BoNT/A (10 pM) but without MjCD preincubation, which served as control. As shown in Figure 7, MjCD pretreatment significantly enhanced the inhibitory effect of all 3 concentrations of BoNT/A. Under control (only BoNT/A and no MjCD) conditions, BoNT/A inhibited twitch tensions completely in about 136.45 ± 18.44 min, while MjCD treatment shortened the time to inhibition of twitch tension to about 68.16 ± 14.34 min. Although, no significantly difference was observed among the 3 concentrations of BoNT/A, preincubation with MjCD significantly shortened the time to 50% inhibition of twitch tension by 10 pM of BoNT/A compared with 1 or 3 pM BoNT/A.

To determine whether MjCD treatment may directly alter the membrane permeability of BoNT/A, we determined the effect of BoNT/A Lc (1 M for 90 min) following MjCD treatment. We expected that if MjCD can directly enhance the internalization of LC/A, then LC/A should suppress the EPF in adult and neonatal (P4) diaphragm NMPS. As shown in Supplementary Figure 5A, LC/A did not cause any paralysis either in the adult or in P4 NMPS.

Previous research suggests that the SNAP-25 isoform determines the differential sensitivity to BoNT/A (Puffer et al., 2001). So, one possibility is that MjCD treatment may enhance the more susceptible form of SNAP-25. We, therefore, analyzed the mRNA levels of SNAP-25 a and b in the developing and adult NMJ but these results were inconclusive due to high cycle time values (data not shown). We therefore, analyzed the expression of SNAP-25 and its cleavage product in the adult and developing NMJ (P4) either treated with BoNT/A (10 pM; 90 min) or pretreatment with sCD (10 mM; 30 min) or MjCD (10 mM; 30 min) prior to BoNT/A treatment (10 pM; 90 min in 40 mM KCl containing HRS). Treatment of BoNT/A (≥ 10 nM sCD) did not cause SNAP-25 cleavage in P4 NMPS, while MjCD pretreatment resulted in BoNT/A-induced cleavage of SNAP-25 in P4 NMPS. However, as expected, BoNT/A cleaved SNAP-25 in the adult NMPS. These results are summarized in Supplementary Figure SC.

The sensitization of BoNT/A to <P7 neonates and the sped up of onset of inhibitory action of BoNT/A in adult NMPS by MjCD treatment raises an important question. That is, whether depletion of cholesterol by MjCD enhanced the expression of BoNT/A receptor SV2 and its interaction with BoNT/A. We analyzed the expression of SV2 in Neuro 2a cells treated with MjCD (10 mM; 30 min) followed by 90 min of treatment with BoNT/A in 40 mM KCl containing HRS. As shown in Supplementary Figures 6A and B, MjCD pretreatment increased SV2 expression in the presence of BoNT/A. Next, we evaluated the interaction between SV2 and BoNT/A Hc (designated as BTX-A-HC or BA-HC) by coimmunoprecipitation experiments using antibodies against SV2 and BA-HC (kind gift from Dr Scott Dessain, Lankenau Institute for Medical Research, PA, USA). The expression of SV2 in control (sCD; 10 mM; 30 min), MjCD (10 mM; 30 min) or BoNT/A (1 nM for 90 min after preincubation with either 10 nM sCD or 10 mM MjCD for 30 min) treated Neuro 2a are illustrated in Figure 8A. We performed immunoprecipitation for SV2 and immunoblotted with SV2 antibody (Figure 8B) or BA-HC antibody (Figure 8C) to show that BoNT/A more efficiently interacted with SV2 following MjCD treatment.

Table 1. Twitch Tension % Post BoNT/A Treatment

| Time After BoNT/A (10 pM) | + Vehicle + BoNT/A | sCD + BoNT/A | MjCD + BoNT/A |
|---------------------------|-------------------|--------------|--------------|
| 0 min                     | 100               | 100          | 100          |
| 30 min                    | 99.02 ± 1.02      | 100 ± 1.11   | 14.44 ± 6.88 |
| 60 min                    | 95.22 ± 4.67      | 94.18 ± 9.80 | 0.01 ± 0.003 |
| 90 min                    | 91.00 ± 12.22     | 84.63 ± 14.19| 0            |

Cholesterol Replenishment, via Water Soluble Cholesterol, Delays the Onset of Inhibitory Effect of BoNT/A

If cholesterol depletion sped up the inhibition of twitch tension by BoNT/A, will cholesterol supplementation with Ch-MjCD prevent this? We performed experiments where NMPS were subjected one of the following treatments: control untreated, BoNT/A treatment in the presence of 10 mM sCD, 30 min in

To determine whether MjCD treatment may directly alter the membrane permeability of BoNT/A, we determined the effect of BoNT/A Lc (1 M for 90 min) following MjCD treatment. We expected that if MjCD can directly enhance the internalization of LC/A, then LC/A should suppress the EPF in adult and neonatal (P4) diaphragm NMPS. As shown in Supplementary Figure 5A, LC/A did not cause any paralysis either in the adult or in P4 NMPS.

Previous research suggests that the SNAP-25 isoform determines the differential sensitivity to BoNT/A (Puffer et al., 2001). So, one possibility is that MjCD treatment may enhance the more susceptible form of SNAP-25. We, therefore, analyzed the mRNA levels of SNAP-25 a and b in the developing and adult NMJ but these results were inconclusive due to high cycle time values (data not shown). We therefore, analyzed the expression of SNAP-25 and its cleavage product in the adult and developing NMJ (P4) either treated with BoNT/A (10 pM; 90 min) or pretreatment with sCD (10 mM; 30 min) or MjCD (10 mM; 30 min) prior to BoNT/A treatment (10 pM; 90 min in 40 mM KCl containing HRS). Treatment of BoNT/A (≥ 10 nM sCD) did not cause SNAP-25 cleavage in P4 NMPS, while MjCD pretreatment resulted in BoNT/A-induced cleavage of SNAP-25 in P4 NMPS. However, as expected, BoNT/A cleaved SNAP-25 in the adult NMPS. These results are summarized in Supplementary Figure SC.

The sensitization of BoNT/A to <P7 neonates and the sped up of onset of inhibitory action of BoNT/A in adult NMPS by MjCD treatment raises an important question. That is, whether depletion of cholesterol by MjCD enhanced the expression of BoNT/A receptor SV2 and its interaction with BoNT/A. We analyzed the expression of SV2 in Neuro 2a cells treated with MjCD (10 mM; 30 min) followed by 90 min of treatment with BoNT/A in 40 mM KCl containing HRS. As shown in Supplementary Figures 6A and B, MjCD pretreatment increased SV2 expression in the presence of BoNT/A. Next, we evaluated the interaction between SV2 and BoNT/A Hc (designated as BTX-A-HC or BA-HC) by coimmunoprecipitation experiments using antibodies against SV2 and BA-HC (kind gift from Dr Scott Dessain, Lankenau Institute for Medical Research, PA, USA). The expression of SV2 in control (sCD; 10 mM; 30 min), MjCD (10 mM; 30 min) or BoNT/A (1 nM for 90 min after preincubation with either 10 nM sCD or 10 mM MjCD for 30 min) treated Neuro 2a are illustrated in Figure 8A. We performed immunoprecipitation for SV2 and immunoblotted with SV2 antibody (Figure 8B) or BA-HC antibody (Figure 8C) to show that BoNT/A more efficiently interacted with SV2 following MjCD treatment.

Table 1. Twitch Tension % Post BoNT/A Treatment

| Time After BoNT/A (10 pM) | + Vehicle + BoNT/A | sCD + BoNT/A | MjCD + BoNT/A |
|---------------------------|-------------------|--------------|--------------|
| 0 min                     | 100               | 100          | 100          |
| 30 min                    | 99.02 ± 1.02      | 100 ± 1.11   | 14.44 ± 6.88 |
| 60 min                    | 95.22 ± 4.67      | 94.18 ± 9.80 | 0.01 ± 0.003 |
| 90 min                    | 91.00 ± 12.22     | 84.63 ± 14.19| 0            |

Cholesterol Replenishment, via Water Soluble Cholesterol, Delays the Onset of Inhibitory Effect of BoNT/A

If cholesterol depletion sped up the inhibition of twitch tension by BoNT/A, will cholesterol supplementation with Ch-MjCD prevent this? We performed experiments where NMPS were subjected one of the following treatments: control untreated, BoNT/A treatment in the presence of 10 mM sCD, 30 min in
10 mM MβCD + wash and then BoNT/A or BoNT/A treatment in the presence of 10 mM cholesterol saturated MβCD. The time course of muscle paralysis (Figure 9A) with these treatments clearly points out that BoNT/A produced complete block of NMT by 95 ± 4.43 min while NMPs treated with MβCD and BoNT/A were blocked within about 38.4 ± 2.66 and 51.2 ± 4.85 min, respectively. The beneficial effect of cholesterol supplementation was evident by longer time (133 ± 5.18 min, Figure 9A) required to produce total paralysis of NMP. The data is best shown by calculating time to 50% block with each treatment (Figure 9B).

**DISCUSSION**

At the adult mammalian NMJ, BoNT/A suppresses ACh release (Baskaran and Thyagarajan, 2014). Although previous research suggests the lack of effect of BoNT/A in neonatal mice following oral administration, the reason for the ability of rat neonates to recover quickly from BoNT/A paralysis or the effect of BoNT/A on immature and developing NMJ have not been studied in detail previously. The enhanced recovery was attributed to return of polyneural innervations in the younger rats (Brown et al., 1981). Also, mice that are <7-days old were resistant to botulism due to negligible systemic absorption of the toxin in these neonates. These data suggest that differential mechanisms regulate toxin’s sensitivity and recovery in neonates compared with adults. However, the role of cholesterol rich LMDs in this process has been analyzed earlier.

This research specifically evaluated the effect of injection of BoNT/A in the hindlimbs of neonates (either <P7 or more than P7) and adult mice. We also evaluated the effect of BoNT/A on the diaphragm NMPs isolated from these groups of mice. We chose to work with diaphragm NMPs due to the ease of access of the tissue as well as due to the nature of diaphragm, being an important tissue for respiratory functions. We present a novel finding that neonatal mice, <7-days old, are resistant to the neuroparalytic effect of BoNT/A, while cholesterol depletion by MβCD sensitized these neonates to BoNT/A.

CDs are routinely used for extracting membrane cholesterol in research. We used 2 kinds of CDs, to perform experiments. αCD, which does not bind cholesterol in the same way as MβCD (Ohtani et al., 1989; Rodal et al., 1999) was used as a control. Since αCD decreased cholera-toxin binding to gangliosides (Ermolinsky et al., 2013), we used it to evaluate its effect on BoNT/A sensitivity at the neonatal and adult NMJ. Both CDs were used at a concentration of 10 mM on neonatal or adult NMJ. Our data suggest that MβCD but not αCD sensitized neonatal mice to BoNT/A. This suggests membrane cholesterol is a critical regulator of BoNT/A sensitivity. Also, it important to note that upon neuroparalysis caused by BoNT/A in MβCD pre-injected <P7 neonates, cannibalism was observed with the mother. So, we could not conduct long-term effects of BoNT/A-induced neuroparalysis and recovery aspects in younger neonates.

Cholesterol is an important regulator of synaptic vesicle recycling and neuromuscular functions. Cholesterol depletion suppresses evoked release but enhances spontaneous release at
the crayfish NMJ (Zamir and Charlton, 2006). Cholesterol rich LMDs control membrane fluidity and help in the clustering of acetylcholine receptors at the post synaptic nerve terminals (Pato et al., 2008; Stetzkowski-Marden et al., 2006). On the other hand, cholesterol depletion by MβCD enhances BoNT/A activity (Petro et al., 2006) and increases spontaneous neurotransmission and enhances spontaneous vesicle endocytosis (Wasser et al., 2007). Consistently, our data suggest a critical role of cholesterol in regulating endocytic mechanism of BoNT/A in the developing NMJ.

Previous published work suggest that cholesterol depletion by MβCD suppressed stimulus evoked release (Zamir and Charlton, 2006). However, preincubation of NMPS 10 mM MβCD for 30 min followed by washing the NMPS with HEPES Ringer buffer for 30 min did not reduce the EPP or EPC amplitudes however sensitized the NMPS to BoNT/A. Also, performing cholesterol depletion by MβCD at 37°C only slightly decreased (up to 5%) the twitch tension compared with control (Supplementary Figs. 3B and C). These data suggest that perturbation of cholesterol levels at the NMJ facilitated BoNT/A uptake and sensitivity. However, it does not rule out an effect of MβCD that is independent of its ability to chelate cholesterol (Ormerod et al., 2012). Nonetheless, the sensitivity of BoNT/A caused by MβCD was not observed when cholesterol saturated MβCD or αCD was used for in vivo BoNT/A injection in the hindlimbs of neonates (Figure 4).

Our data also suggest that the sensitization of neonatal NMPS is associated with a corresponding increase in the frequency of mEPP in both adult and neonatal NMPS (Figure 3C). This observation raised an important question—whether increase in mEPP would facilitate BoNT/A uptake? BoNT/A uptake in NMP is increased upon stimulation (Rummel et al., 2009). It has been shown previously that treatment of NMPS with hyperkalemic buffer (40 or 75 mM KCl extracellularly) significantly facilitated BoNT/A uptake (Supplementary Figure 2) and increased mEPPs in neonatal and adult NMPS (Figure 3C). Therefore, it is reasonable to speculate that MβCD would facilitate BoNT/A uptake by increasing spontaneous vesicle fusion, which would expose the neurotoxin to the NMPs.

Figure 8. MβCD increases SV2 expression and its interaction with BoNT/A in Neuro 2A cells. A, Western blot showing the expression of SV2 in Input. B, immunoprecipitation with SV2 antibody shows more SV2 under MβCD treated conditions. C, Coimmunoprecipitation showing enhanced interaction of SV2 with BoNT/A under MβCD treated conditions.

Figure 9. Cholesterol supplementation via Ch-MβCD with water soluble cholesterol delays the time to inhibit 50% twitch tension in adult diaphragm NMPS. A, Time courses of stimulus evoked twitch tension in adult diaphragm NMPS treated with either αCD alone (10 mM; 30 min; control), or BoNT/A with and without either MβCD (10 mM; for 30 min preincubation) or MβCD saturated with cholesterol (10 mM; present throughout the experiment). B, Bar graphs represent the mean time to inhibit 50% of stimulus evoked twitch tension ± SEM followed by BoNT/A (10 pM) under the conditions mentioned earlier (n = 5–8 NMPS for each condition).
more synaptic vesicle glycoprotein (SV2) to the membrane to facilitate BoNT/A uptake. However, the effect of MβCD on gangliosides (another receptor for BoNT/A) still remains to be elucidated at the NMJ. Therefore, an alternate possibility is that MβCD-mediated cholesterol depletion alters the clustering of gangliosides, which would facilitate BoNT/A uptake. Further studies are required to address this mechanism. A third possibility is that the expression of endocytic machinery that governs BoNT/A uptake could not be fully developed in younger neonates. Perhaps, cholesterol depletion induced reorganization of lipid rafts may facilitate BoNT/A endocytosis. Therefore, further studies are required to understand the mechanisms that underlie the resistance to BoNT/A in the developing NMJ.

At the MNTs, synaptic vesicle glycoproteins (SV2), along with gangliosides functions as the receptor for BoNT/A. Experiments performed to evaluate the effect of MβCD on SV2 expression in Neuro 2a cells suggest that MβCD treatment (10 mM for 30 min) significantly increased SV2 expression in these cells. Also, MβCD treatment enhanced the interaction between SV2 and BoNT/A (Figs. 8B and C) in Neuro 2a cells suggesting the facilitation of SV2 availability for toxin binding (Figure 8). Consistent to this observation, a previous report suggests that cholesterol depletion or lipid raft inhibition facilitated the binding of BoNT/A in Neuro 2a cells (Ayyar and Atassi, 2016). Moreover, disruption of lipid rafts enhanced the activity of BoNT/A in cultured Neuro 2a cells possibly by increasing the spontaneous vesicle endocytosis due to cholesterol depletion (Wasser et al., 2007).

If cholesterol depletion sensitizes neonatal mice to BoNT/A and enhanced the effect of BoNT/A in adult NMJs, supplementation of cholesterol via water soluble cholesterol should prevent the effect of MβCD. Consistent to this notion, cholesterol saturated MβCD failed to cause neuropaTHYAGARAJAN ET AL | 187

Health under Award Number (8P20GM103432-12) and American Association of Colleges of Pharmacy New Investigator Award to B.T. and F.M. Kirby Foundation Award to J.J.M.

REFERENCES

Ayyar, B. V., and Atassi, M. Z. (2016). Effects of membrane properties on the binding activities of the HN and HC heavy-chain domains of botulinum neurotoxin A. Biochim. Biophys. Acta 1864, 1678–1685.

Baskaran, P., Lehmann, T. E., Topchiy, E., Thirunavukkarasu, N., Cai, S., Singh, B. R., Deshpande, S., and Thyagarajan, B. (2013). Effects of enzymatically inactive recombinant botulinum neurotoxin type A at the mouse neuromuscular junctions. Toxicon 72, 71–80.

Baskaran, P., and Thyagarajan, B. (2014). Acute and chronic effects of botulinum neurotoxin a on the mammalian neuromuscular junction. Musc. Nerve 50, 206–215.

Brown, M. C., Holland, R. L., and Hopkins, W. G. (1981). Restoration of focal multiple innervation in rat muscles by transmission block during a critical stage of development. J. Physiol. 318, 355–364.

Brumell, J. H., and Grinstein, S. (2003). Role of lipid-mediated signal transduction in bacterial internalization. Cell Microbiol. 5, 287–297.

Colon-Saez, J. O., and Yakel, J. L. (2011). The alpha7 nicotinic acetylcholine receptor function in hippocampal neurons is regulated by the lipid composition of the plasma membrane. J. Physiol. 589(Pt 13), 3163–3174. 10.1113/jphysiol.2011.209494.

Cubi, R., Candalija, A., Ortega, A., Gil, C., and Aguilera, J. (2013). Tetanus toxin Hc fragment induces the formation of ceramide platforms and protects neuronal cells against oxidative stress. PLoS One 8, e68055.

Dong, M., Yeh, F., Tepp, W. H., Dean, C., Johnson, E. A., Janz, R., and Chapman, E. R. (2006). SV2 is the protein receptor for botulinum neurotoxin A. Science 312, 592–596.

Ermolinsky, B., Peredelchuk, M., and Provenzano, D. (2013). alpha-Cyclodextrin decreases cholera toxin binding to GM1-gangliosides J. Med. Microbiol. 62(Pt 7), 1011–1014.

Grohovaz, F., Fesces, R., and Haimann, C. (1989). Dual effect of potassium on transmitter exocytosis. Cell Biol. Int. Rep. 13, 1085–1095.

Gutmann, E., L. M., Medawar, P. B., and Young, J. Z. (1942). The rate of regeneration of the nerve. J. Exp. Biol. 19, 14–44.

Herrerios, J., Ng, T., and Schiavo, G. (2001). Lipid rafts act as specialized domains for tetanus toxin binding and internalization into neurons. Mol. Cell. Biol. 12, 2947–2960.

Kerzmann, A., and Feig, A. L. (2006). Cholesterol, it’s not just for heart disease anymore. ACS Chem. Biol. 1, 141–144.

Kitamura, Y., Matsuka, Y., Spigelman, I., Ishihara, Y., Yamamoto, Y., Sonoyama, W., Kamioka, H., Yamashiro, T., Kuboki, T., and Oguma, K. (2009). Botulinum toxin type A (150 kDa) decreases exaggerated neuromuscular transmitter release from trigeminal ganglion neurons and relieves neuropathy behaviors induced by infraorbital nerve constriction. Neuroscience 159, 1422–1429.

Krstavsova, V. V., Petrov, A. M., Vasil’ev, A. N., Zefirov, A. L., and Krivoi, I. I. (2015). Role of cholesterol in the maintenance of endplate electogenesis in rat diaphragm. Bull. Exp. Biol. Med. 158, 298–300.

Mahrhold, S., Rummel, A., Bigalke, H., Davletov, B., and Binz, T. (2006). The synaptic vesicle protein 2C mediates the uptake of botulinum neurotoxin A into phrenic nerves. FEBS Lett. 580, 2011–2014.
